Day: March 1, 2023

Surrey Bancorp Announces First Quarter Cash Dividend of $0.12 per share of Common Stock

Surrey Bancorp Announces First Quarter Cash Dividend of $0.12 per share of Common Stock

MOUNT AIRY, N.C., March 01, 2023 (GLOBE NEWSWIRE) — The Board of Directors of Surrey Bancorp (“the Company”, Pink Sheets: SRYB) has declared a quarterly cash dividend of 12 cents ($0.12) per share on the Company’s common stock. The cash dividend is payable on April 10, 2023, to shareholders of record as of the close of business on March 17, 2023. Ted Ashby, CEO of Surrey Bancorp, stated the dividend was based on the Company’s current operating results, its strong financial condition and a commitment to delivering shareholder value. Surrey Bancorp is the bank holding company for Surrey Bank & Trust (the “Bank”) and is located at 145 North Renfro Street, Mount Airy, North Carolina. The Bank operates full service branch offices at 145 North Renfro Street, and 2050 Rockford Street in Mount Airy and a limited service branch at...

Continue reading

Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica

Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica

Three times more patients treated with Kevzara achieved sustained remission compared to placebo in Phase 3 trial Kevzara now approved to treat two chronic inflammatory disorders TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Kevzara® (sarilumab) for the treatment of polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. “Polymyalgia rheumatica can be an incapacitating disease, causing painful disease flares in multiple parts of the body that leave people fatigued and unable to fully perform everyday activities. Corticosteroids have been the...

Continue reading

Dynamic Technologies Group Provides Corporate Update

Dynamic Technologies Group Provides Corporate Update

TORONTO, Feb. 28, 2023 (GLOBE NEWSWIRE) — Dynamic Technologies Group Inc. (TSXV: DTG, OTC:ERILF) (“Dynamic”, “Company”, “we” and “our”) with reference to our prior new release dated August 8, 2022 announces that its USD$16 million senior secured credit facilities with Promising Expert Limited (“PEL”) matured on February 28, 2023 (the “PEL Credit Facilities”) and the Company is currently in default for non-payment of the same. The default under the PEL Credit Facilities constitutes a cross-default under the terms of the Company’s USD$2 million subordinated secured loan with Export Development Canada (“EDC”). The Company is having ongoing discussions with PEL, who remains supportive of the Company. Based on those discussions, the Company does not expect PEL to issue a demand for payment at this time or to take any immediate steps...

Continue reading

PHX Energy Announces Strongest Fourth Quarter and Year End Results In Its History

PHX Energy Announces Strongest Fourth Quarter and Year End Results In Its History

Capital Expenditures Capital Expenditures CALGARY, Alberta, Feb. 28, 2023 (GLOBE NEWSWIRE) — Fourth Quarter Highlights For the three-month period ended December 31, 2022, PHX Energy generated consolidated revenue of $157.8 million, the highest level of quarterly revenue in the Corporation’s history and an increase of 54 percent from the fourth quarter of 2021. Adjusted EBITDA(1) from continuing operations increased to $33.9 million, 21 percent of consolidated revenue(1). This is also PHX Energy’s highest level of quarterly adjusted EBITDA and all-time record as a percentage of consolidated revenue. Included in the 2022-quarter’s adjusted EBITDA is $6.9 million in cash-settled share-based compensation expense. Excluding cash-settled share-based compensation expense, adjusted EBITDA from continuing operations(1) in the fourth...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.